The enrollment milestone removes a key timeline risk for the TEBE-AM readout. Monitor for topline OS data expected by end of 2026 — a positive result could significantly expand KIMMTRAK's addressable market beyond uveal melanoma into the larger cutaneous melanoma setting.
Price Chart
Executive Summary
Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evaluating tebentafusp (KIMMTRAK) in previously treated advanced melanoma. Topline overall survival data is expected as early as end of 2026. This is a positive clinical milestone that de-risks the trial timeline but provides no efficacy data yet.
Key Facts
- Target enrollment of 540 patients achieved in Phase 3 TEBE-AM trial of tebentafusp in previously treated advanced melanoma
- Topline overall survival data expected as early as end of 2026
- Trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab vs investigator's choice
- Primary endpoint is overall survival
- Company estimates up to 4,000 HLA-A*02:01-positive patients in the US and Europe with this indication
Financial Impact
No financial data in filing; clinical milestone de-risks a potential label expansion opportunity for KIMMTRAK into a larger melanoma market (cutaneous vs current uveal melanoma indication)
Risk Factors
- No efficacy data yet — OS results may fail to meet statistical significance
- Competition from existing PD-1 and BRAF-targeted therapies in post-PD1 advanced melanoma
- KIMMTRAK carries a boxed warning for Cytokine Release Syndrome which may limit adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001671927-26-000026 |
| Document: pressrelease-tebexamenroll.htm | 0001671927-26-000026 |
| Document: 0001671927-26-000026-index-headers.html | 0001671927-26-000026 |
| Document: 0001671927-26-000026-index.html | 0001671927-26-000026 |
| Document: 0001671927-26-000026.txt | 0001671927-26-000026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $32.46 $32.18 | ▼ −0.86% | ▼ −0.97% | $29.71 (−8.47%) |
Aug 6, 2026 8w ago | 8-K | $34.50 $34.20 | ▼ −0.87% | ▼ −2.08% | $29.71 (−13.88%) |
May 31, 2026 17w ago | Press Release | $29.13 $28.29 | ▼ −2.88% | ▼ −0.13% | $29.71 (+1.99%) |
Apr 19, 2026 23w ago | Press Release | $31.46 $28.56 | ▼ −9.22% | ▼ −10.13% | $29.71 (−5.56%) |
Apr 8, 2026 25w ago | 144 | $31.85 $31.64 | ▼ −0.66% | ▼ −4.18% | $29.71 (−6.72%) |
Mar 17, 2026 28w ago | Press Release | $30.04 $30.28 | ▲ +0.80% | ▲ +1.51% | $29.71 (−1.10%) |
Feb 25, 2026 31w ago | 8-K | $32.16 $33.73 | ▲ +4.88% | ▲ +5.98% | $29.71 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access